A scale to monitor progression and treatment of mitochondrial disease in children

C. Phoenix, A. M. Schaefer, J. L. Elson, Eva Morava-Kozicz, M. Bugiani, G. Uziel, J. A. Smeitink, D. M. Turnbull, R. McFarland

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Mitochondrial diseases affect all age groups, but those with childhood onset often seem to experience the greatest burden of disability. In some paediatric patients this can be explained by a cumulative disability acquired over many years. In others, additional factors, including the nature and severity of the molecular defect, must be considered. To date, no large-scale studies have attempted to document the natural history of paediatric mitochondrial disease. This is in part at least, because no assessment tool has been available to plot the temporal course of a disease with such a diverse clinical spectrum. This paper describes how a practical and semi-quantitative rating scale has been devised for children with mitochondrial disease, the Newcastle paediatric mitochondrial disease scale (NPMDS). The scale is multi-dimensional and reproducible, offering a tool through which mitochondrial disease progression can be objectively monitored. We anticipate that use of this tool will facilitate both longitudinal natural history studies and the assessment of future therapeutic interventions.

Original languageEnglish (US)
Pages (from-to)814-820
Number of pages7
JournalNeuromuscular Disorders
Volume16
Issue number12
DOIs
StatePublished - Dec 1 2006
Externally publishedYes

Fingerprint

Mitochondrial Diseases
Pediatrics
Therapeutics
Natural History
Disease Progression
Age Groups

Keywords

  • Disease progression
  • Mitochondrial disease
  • Natural history
  • Paediatric
  • Prospective rating scale

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Neurology
  • Clinical Neurology
  • Genetics(clinical)

Cite this

Phoenix, C., Schaefer, A. M., Elson, J. L., Morava-Kozicz, E., Bugiani, M., Uziel, G., ... McFarland, R. (2006). A scale to monitor progression and treatment of mitochondrial disease in children. Neuromuscular Disorders, 16(12), 814-820. https://doi.org/10.1016/j.nmd.2006.08.006

A scale to monitor progression and treatment of mitochondrial disease in children. / Phoenix, C.; Schaefer, A. M.; Elson, J. L.; Morava-Kozicz, Eva; Bugiani, M.; Uziel, G.; Smeitink, J. A.; Turnbull, D. M.; McFarland, R.

In: Neuromuscular Disorders, Vol. 16, No. 12, 01.12.2006, p. 814-820.

Research output: Contribution to journalArticle

Phoenix, C, Schaefer, AM, Elson, JL, Morava-Kozicz, E, Bugiani, M, Uziel, G, Smeitink, JA, Turnbull, DM & McFarland, R 2006, 'A scale to monitor progression and treatment of mitochondrial disease in children', Neuromuscular Disorders, vol. 16, no. 12, pp. 814-820. https://doi.org/10.1016/j.nmd.2006.08.006
Phoenix, C. ; Schaefer, A. M. ; Elson, J. L. ; Morava-Kozicz, Eva ; Bugiani, M. ; Uziel, G. ; Smeitink, J. A. ; Turnbull, D. M. ; McFarland, R. / A scale to monitor progression and treatment of mitochondrial disease in children. In: Neuromuscular Disorders. 2006 ; Vol. 16, No. 12. pp. 814-820.
@article{8599d3197bb34fa4bea463f8f3f07c5c,
title = "A scale to monitor progression and treatment of mitochondrial disease in children",
abstract = "Mitochondrial diseases affect all age groups, but those with childhood onset often seem to experience the greatest burden of disability. In some paediatric patients this can be explained by a cumulative disability acquired over many years. In others, additional factors, including the nature and severity of the molecular defect, must be considered. To date, no large-scale studies have attempted to document the natural history of paediatric mitochondrial disease. This is in part at least, because no assessment tool has been available to plot the temporal course of a disease with such a diverse clinical spectrum. This paper describes how a practical and semi-quantitative rating scale has been devised for children with mitochondrial disease, the Newcastle paediatric mitochondrial disease scale (NPMDS). The scale is multi-dimensional and reproducible, offering a tool through which mitochondrial disease progression can be objectively monitored. We anticipate that use of this tool will facilitate both longitudinal natural history studies and the assessment of future therapeutic interventions.",
keywords = "Disease progression, Mitochondrial disease, Natural history, Paediatric, Prospective rating scale",
author = "C. Phoenix and Schaefer, {A. M.} and Elson, {J. L.} and Eva Morava-Kozicz and M. Bugiani and G. Uziel and Smeitink, {J. A.} and Turnbull, {D. M.} and R. McFarland",
year = "2006",
month = "12",
day = "1",
doi = "10.1016/j.nmd.2006.08.006",
language = "English (US)",
volume = "16",
pages = "814--820",
journal = "Neuromuscular Disorders",
issn = "0960-8966",
publisher = "Elsevier Limited",
number = "12",

}

TY - JOUR

T1 - A scale to monitor progression and treatment of mitochondrial disease in children

AU - Phoenix, C.

AU - Schaefer, A. M.

AU - Elson, J. L.

AU - Morava-Kozicz, Eva

AU - Bugiani, M.

AU - Uziel, G.

AU - Smeitink, J. A.

AU - Turnbull, D. M.

AU - McFarland, R.

PY - 2006/12/1

Y1 - 2006/12/1

N2 - Mitochondrial diseases affect all age groups, but those with childhood onset often seem to experience the greatest burden of disability. In some paediatric patients this can be explained by a cumulative disability acquired over many years. In others, additional factors, including the nature and severity of the molecular defect, must be considered. To date, no large-scale studies have attempted to document the natural history of paediatric mitochondrial disease. This is in part at least, because no assessment tool has been available to plot the temporal course of a disease with such a diverse clinical spectrum. This paper describes how a practical and semi-quantitative rating scale has been devised for children with mitochondrial disease, the Newcastle paediatric mitochondrial disease scale (NPMDS). The scale is multi-dimensional and reproducible, offering a tool through which mitochondrial disease progression can be objectively monitored. We anticipate that use of this tool will facilitate both longitudinal natural history studies and the assessment of future therapeutic interventions.

AB - Mitochondrial diseases affect all age groups, but those with childhood onset often seem to experience the greatest burden of disability. In some paediatric patients this can be explained by a cumulative disability acquired over many years. In others, additional factors, including the nature and severity of the molecular defect, must be considered. To date, no large-scale studies have attempted to document the natural history of paediatric mitochondrial disease. This is in part at least, because no assessment tool has been available to plot the temporal course of a disease with such a diverse clinical spectrum. This paper describes how a practical and semi-quantitative rating scale has been devised for children with mitochondrial disease, the Newcastle paediatric mitochondrial disease scale (NPMDS). The scale is multi-dimensional and reproducible, offering a tool through which mitochondrial disease progression can be objectively monitored. We anticipate that use of this tool will facilitate both longitudinal natural history studies and the assessment of future therapeutic interventions.

KW - Disease progression

KW - Mitochondrial disease

KW - Natural history

KW - Paediatric

KW - Prospective rating scale

UR - http://www.scopus.com/inward/record.url?scp=33845202246&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33845202246&partnerID=8YFLogxK

U2 - 10.1016/j.nmd.2006.08.006

DO - 10.1016/j.nmd.2006.08.006

M3 - Article

C2 - 17123819

AN - SCOPUS:33845202246

VL - 16

SP - 814

EP - 820

JO - Neuromuscular Disorders

JF - Neuromuscular Disorders

SN - 0960-8966

IS - 12

ER -